Exercise Intervention to Reverse Frailty
Launched by UNIVERSITY OF BRITISH COLUMBIA · Nov 1, 2016
Trial Information
Current as of May 04, 2025
Unknown status
Keywords
ClinConnect Summary
Frailty is term widely used to denote a multidimensional syndrome associated with the loss of physical and cognitive reserve capacity that makes an individual vulnerable to cumulative clinical health conditions. The level of frailty can be classified as one of three phenotypes (non-frail; pre-frail, frail) using the Cardiac Health Study frailty index (CHS). The CHS assesses the number of physical deficits expressed by an individual. These deficits include (unexplained weight loss, poor grip strength, feelings of exhaustion, slowed gait, and low levels of physical activity). An individual wh...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female
- • 65-95 years of age
- • Free of any serious injury in the last 6 months
- • Deemed to express the pre-frailty phenotype, meaning they are classified as: Pre-frail according to the CHS and "Vulnerable" and/or "Mildly Frail" according to the CFS
- • Confirmation of pre-frailty based-upon walking speed of 1.0-1.5 meters/second
- • Assessed as healthy for exercise according to responses from the PAR-Q+
- • Are consider safe for exercise based on the evaluation by a Certified Exercise Physiologist (CEP).
- • Do not have any cognitive impairment, a score of ≥26 (total possible score 30) indicates normal cognitive function as measured by MoCA tool
- • Participants must be able to speak and read English fluently
- Exclusion Criteria:
- • Male
- • Below 65 years of age or above 95
- • Have suffered a serious injury in the last 6 months
- • Not deemed pre-frail based on scores from the CHS and CFS
- • Walking speed slower or faster than 1.0-1.5 m/s
- • Assessed as unhealthy for exercise according to responses from the PAR-Q+
- • Are consider unsafe for exercise based on the evaluation of the CSEP-CEP
- • Have possible cognitive impairment as measured by the MoCA tool (score \<26)
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kelwona, British Columbia, Canada
Patients applied
Trial Officials
Gareth R Jones, PhD
Principal Investigator
UBC Okanagan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials